Perioperative Management of Direct Oral Anticoagulants (DOACs): A Systemic Review

Health Services Insights

Volumn 9, Issue , 2016, Pages

  Sunkara, Tagore ^a   Ofori, Emmanuel ^a   Zarubin, Vadim ^a   Caughey, Megan E ^b   Gaduputi, Vinaya ^c   Reddy, Madhavi ^a  

^a BROOKLYN HOSPITAL CENTER   (United States)

^b NEW YORK INSTITUTE OF TECHNOLOGY   (United States)

^c SBH Health System   (United States)

Author keywords

direct oral anticoagulants; DOACs; new oral anticoagulants

Indexed keywords

EID: 85027787210     PISSN: None     EISSN: 11786329     Source Type: Journal    
DOI: 10.4137/HSI.S40701     Document Type: Review

References (36)

1. Riva N., Lip G., A new era for anticoagulation in atrial fibrillation. Which anticoagulant should we choose for long-term prevention of thromboembolic complications in patients with atrial fibrillation? Pol Arch Med Wewn. 2012; 122: 45–53.
2. Douketis J.D., Spyropoulos A.C., Spencer F.A., et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141: 326S–350S.
3. Tran H., Joseph J., Young L., et al. New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Intern Med J. 2014; 44(6): 525–536.
4. Turpie A.G.G., Kreutz R., Llau J., Norrving B., Haas S., Management consensus guidance for the use of rivaroxaban—an oral, direct factor Xa inhibitor. Thromb Haemost. 2012; 108(5): 876–886.
5. Spyropoulos A.C., Douketis J.D., How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood. 2012; 120(15): 2954–2962.
6. Schulman S., Angerås U., Bergqvist D., Eriksson B., Lassen M.R., Fisher W., Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost. 2010; 8(1): 202–204.
7. Mehran R., Rao S.V., Bhatt D.L., et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation. 2011; 123(23): 2736–2747.
8. Douketis J.D., Perioperative management of patients who are receiving warfarin therapy: an evidence-based and practical approach. Blood. 2011; 117(19): 5044–5049.
9. Sherwood M.W., Douketis J.D., Patel M.R., et al. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation. 2014; 129(18): 1850–1859.
10. Zehnder J.L., Drugs used in disorders of coagulation. In: Katzung B.G., Trevor A.J., eds. Basic & Clinical Pharmacology, 13e. NewYork, NY: McGraw-Hill; 2015. Available at: http://accessmedicine.mhmedical.com.arktos.nyit.edu/content.aspx?bookid=1193&Sectionid=69108955. Accessed August 31, 2016.
11. Dabigatran: drug information. In: Post T.W., ed. UpToDate. Waltham, MA: UpToDate; 2016.
12. Stangier J., Rathgen K., Stähle H., Mazur D., Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate. Clin Pharmacokinet. 2010; 49(4): 259–268.
13. PRADAXAå (dabigatran etexilate mesylate). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2010, 2012, 2013.
14. Stangier J., Eriksson B.I., Dahl O.E., et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol. 2005; 45(5): 555–565.
15. Pollack C.V., Reilly P.A., Eikelboom J., et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015; 373(6): 511–520.
16. Eikelboom J.W., Connolly S.J., Brueckmann M., et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013; 369(13): 1206–1214.
17. Samama M., Contant G., Spiro T.E., et al. Laboratory assessment of rivaroxaban: a review. Thromb J. 2013; 11(1): 11.
18. Healey J.S., Eikelboom J., Douketis J., et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the randomized evaluation of long-term anticoagulation therapy (RE-LY) randomized trial. Circulation. 2012; 126(3): 343–348.
19. Schulman S., Carrier M., Lee AY Y., et al. Perioperative management of dabigatran clinical perspective. Circulation. 2015; 132(3): 167–173.
20. Acosta R.D., Abraham N.S., Chandrasekhara V., et al. The management of antithrombotic agents for patients undergoing GI endoscopy. Gastrointest Endosc. 2016; 83(1): 3–16.
21. Rivaroxaban: drug information. In: Post T.W., ed. UpToDate. Waltham, MA: UpToDate; 2016.
22. Xarelto (rivaroxaban). Titusville, NJ: Janssen Pharmaceuticals, Inc; 2011, 2016.
23. Eikelboom J., Sobieraj-Teague M., Ginsberg J.S., Chapter 261. Anticoagulant therapy. In: McKean S.C., Ross J.J., Dressler D.D., Brotman D.J., Ginsberg J.S., eds. Principles and Practice of Hospital Medicine. New York, N Y: McGraw-Hill; 2012. Available at: http://accessmedicine.mhmedical.com.arktos.nyit.edu/content.aspx?bookid=496&Sectionid=41304257. Accessed September 11, 2016.
24. EINSTEIN Investigators, Bauersachs R., Berkowitz S., et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010; 363(26): 2499–2510.
25. Apixaban: drug information. In: Post T.W., ed. UpToDate. Waltham, MA: UpToDate; 2016.
26. ELIQUIS (apixaban). Princeton, NJ; New York, NY: Bristol-Myers Squibb Company & Pfizer Inc; 2012, 2016.
27. Trevor A.J., Katzung B.G., Kruidering-Hall M., Drugs used in coagulation disorders. In: Trevor A.J., Katzung B.G., Kruidering-Hall M., eds. Katzung & Trevor's Pharmacology: Examination & Board Review, 11e. New York, NY: McGraw-Hill; 2015. Available at: http://accessmedicine.mhmedical.com.arktos.nyit.edu/content.aspx?bookid=1568&Sectionid=9570369. Accessed September 11, 2016.
28. Garcia D., Alexander J.H., Wallentin L., et al. Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. Blood. 2014; 124(25): 3692–3698.
29. SAVAYSA (edoxaban). Parsippany, NJ: Daiichi Sankyo, Inc; 2015.
30. Edoxaban: drug information. In: Post T.W., ed. UpToDate. Waltham, MA: UpToDate; 2016.
31. Giugliano R P., Ruff C.T., Braunwald E., et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369(22): 2093–2104.
32. Martin K., Beyer-Westendorf J., Davidson B.L., Huisman M.V., Sandset P.M., Moll S., Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost. 2016; 14(6): 1308–1313.
33. Weitz J.I., Antiplatelet, anticoagulant, and fibrinolytic drugs. In: Kasper D., Fauci A., Hauser S., Longo D., Jameson J., Loscalzo J., eds. Harrison's Principles of Internal Medicine, 19e. New York, N Y: McGraw-Hill; 2015. Available at: http://accessmedicine.mhmedical.com.arktos.nyit.edu/content.aspx?bookid=1130&Sectionid=79732627. Accessed September 01, 2016.
34. Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013; 369(15): 1406–1415.
35. Douketis J., Weitz J., Murphy S., et al. Perioperative adverse outcomes in patients with atrial fibrillation taking edoxaban or warfarin: analysis of the ENGAGE AF-TIMI 48 TRIAL. J Am Coll Cardiol. 2015; 65(10S). A2092.
36. Zalpour A., Oo T.H., Update on edoxaban for the prevention and treatment of thromboembolism: clinical applications based on current evidence. Adv Hematol. 2015; 2015: 920361, 19.